An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C

Raf Crabbé Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]

Grégoire Vuagniaux Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]

Jean-Maurice Dumont Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]

Valérie Nicolas-Métral Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]

Judith Marfurt Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]

Laura Novaroli Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]

Abstract

Debio 025 is a cyclophilin (Cyp) inhibitor without calcineurin-binding properties. The drug inhibits viral replication of genotype 1b and 2a replicons in nanomolar concentrations and shows an additive to synergistic antiviral effect with interferon, ribavirin, and specifically targeted antiviral therapy for hepatitis C (STAT-C) drugs. There is no cross-resistance with protease and polymerase inhibitors. In humans, Debio 025 has shown activity against genotypes 1, 2, 3, and 4, and displays an additive antiviral effect with pegylated interferon (peg-IFN)α2a in genotype 1 and 4 patients. The most prominent side effect is reversible hyperbilirubinaemia caused by inhibition of biliary transporters. Debio 025 is a potent anti-HCV drug, with a novel mechanism of action and an efficacy profile that makes it an attractive candidate for combination with current and future HCV treatments.

Keywords::

Acknowledgments

We would like to thank C Hansson Bondallaz for excellent editorial assistance.

Notes

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C

Information for

Open access

Opportunities

Help and information

An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C

Abstract

Acknowledgments

Notes

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature